To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Tesofensine Acts Directly on Fat Mass in Obese Patients: Presented at ECO
URL: http://www.pslgroup.com/dg/221E36.htm
Doctor's Guide
May 23, 2008

By Timothy A. O'Leary

GENEVA -- May 23, 2008 -- The experimental anti-obesity drug tesofensine not only helps patients with obesity to lose weight, but also helps them to lose the right kind of weight and in the right places, researchers reported here at the 16th European Congress on Obesity (ECO).

Danish researchers studied the effects of tesofensine on body composition, including body weight, fat mass, waist circumference, and sagittal diameter (a measure of the upper abdomen). The team was led by Anders Sjodin, MD, Associate Professor, Department of Human Nutrition, University of Copenhagen, Copenhagen, Denmark.

The study, presented on May 16, was a randomised, double-blind, placebo-controlled, phase 2b trial of 203 otherwise healthy men and women with obesity (defined as body mass index between 30 and 40).

After a diet and exercise lead-in period of 2 weeks, the patients were put on 24 weeks of tesofensine in once-daily doses of 0.25 mg, 0.5 mg, 1.0 mg, or corresponding placebo.

Body weight loss was 2.3 kg for the placebo group, 6.8 kg for the 0.25-mg group, 11.4 kg for the 0.50-mg group, and 12.7 kg for the 1.0-mg group.

Sagittal diameter decreased 0.6 cm in the placebo group, 2.1 cm in the 0.25-mg group, 3.3 cm in the 0.5-mg group, and 3.5 cm in the 1.0-mg group.

Waist circumference decreased 3.0 cm in the placebo group, 6.4 cm in the 0.25-mg group, 9.8 cm in the 0.5-mg group, and 9.8 cm in the 1.0-mg group.

Of particular importance to the research were the measurements for reduction in fat mass. Fat mass decreased 2.8 kg in the placebo group, 5.7 kg in the 0.25-mg group, 9.2 kg in the 0.5-mg group, and 10.1 kg in the 1.0-mg group. The reductions accounted for 108% of total weight loss in the placebo group, 85% in the 0.25-mg group, 81% in the 0.5-mg group, and 79% in the 1.0-mg group.

"Eighty percent [of the weight reduction] could be accounted for by a reduction in fat mass," said Dr. Sjodin.

"The concomitant decrease seen in sagittal diameter and waist circumference, therefore indicates that tenofensine is highly effective in reducing central obesity," Dr. Sjodin concluded.

Dr. Sjodin and his collaborators also claimed that tesofensine was shown to result in weight reductions that are twice that produced by currently available anti-obesity drugs.

Tesofensine acts by inhibiting the presynaptic uptake of the neurotransmitters noradrenaline, dopamine, and serotonin.

This study was funded by NeuroSearch A/S.


[Presentation title: The Effects of Tesofensine on Body Composition in Obese Subjects. Abstract T2:PS.10]

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.